ProteoGenix focuses exclusively on conditions related to pregnancy and neonatal management—two of the top three most expensive conditions treated in hospitals.¹ In 2008, the National Institutes of Health estimated nearly 500,000 babies born in the United States (one in every eight births) are born preterm, and this number continues to rise. Further, NIH stated “preterm birth is a major cause of infant death and places infants at increased risk for serious life-long disability. The annual increased cost due to preterm birth in the United States is estimated to be $26 billion.” ² It is also estimated that preterm infants account for half of total hospital charges for newborn care in United States.³ In addition to economic costs, complications related to pregnancy and preterm births, infants have significant emotional, social and long-term medical impacts.

ProteoGenix’ scientific discovery of the Proteomic Map of Pregnancy and development of nucleic acid-based molecular diagnostic tests optimized for use in the key biological fluids of pregnancy, open the door to the creation of effective, minimally-invasive diagnostics that can allow early and accurate identification of significant disorders of pregnancy and neonates. Some of these disorders can be difficult to identify with currently available diagnostic tools. Early and accurate identification of these disorders allows timely intervention to improve the health and well-being of pregnant women and their babies.

• Intraamniotic Infection (IAI)

• Neonatal Sepsis

• Preterm Birth

• Preeclampsia

• Down Syndrome